Skip to content
value.today
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG

Formerly Inception Genomics AG

Total raised
$35 M
1 round on record
Latest round
$35 M
Oct 2016
First round on record
Oct 2016
Today
Went public
See the company page

CRISPR Therapeutics AG is listed today as CRISPR Therapeutics AG: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of CRISPR Therapeutics AG
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2020$1 MPrivate placement after listingUnder $2 million

CRISPR Therapeutics AG: Private sale, Mar 2020

Investors in this round

1 investor had bought by the notice of Apr 10, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for CRISPR Therapeutics AG as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Switzerland

People named in the notice

  • James Kasinger · Executive Officer
  • Lawrence Klein · Executive Officer
  • Michael Tomsicek · Executive Officer
  • Rodger Novak · Executive Officer, Director
  • Samarth Kulkarni · Executive Officer, Director
  • Tony Ho · Executive Officer
  • Ali Behbahani · Director
  • Bradley Bolzon · Director
  • John Greene · Director
  • Katherine High · Director
  • Simeon George · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James R. Kasinger, General Counsel. Source: SEC Form D and 1 amendment, newest notice filed Apr 10, 2020. Read the notice at the SEC.

equitySEC
Oct 2016$35 MNo. 1$10 to $50 million

CRISPR Therapeutics AG: Raise no. 1, Oct 2016

Investors in this round

1 investor had bought by the notice of Nov 4, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for CRISPR Therapeutics AG as a whole in other filings: see Investors below.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Switzerland

People named in the notice

  • Kala Ante Subramanian · Executive Officer
  • Marc J. Becker · Executive Officer
  • Rodger Novak · Executive Officer, Director
  • Samarth Ante Kulkarni · Executive Officer
  • Sven Ante Lundberg · Executive Officer
  • Tyler Ante Dylan-Hyde · Executive Officer
  • Ali Anthony Behbahani · Director
  • Bradley Anthony Bolzon · Director
  • Kurt J. von Emster · Director
  • N. Anthony Coles · Director
  • Pablo J. Cagnoni · Director
  • Simeon J. George · Director
  • Thomas J. Woiwode · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Rodger Novak, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 4, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company CRISPR Therapeutics AG, its revenue in fiscal 2025 came from these product and service lines: Grant Revenue $3.51 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • CRISPR Therapeutics AG chose not to state its revenue in its newest notice of a funding round (Apr 2020).

    SEC Form D · Apr 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2020

Products and services#

No products or services of CRISPR Therapeutics AG are on record.

Investors#

10 named in official filings. Open an investor to see everything it has backed.

Investors in CRISPR Therapeutics AG
InvestorKindAmountRoundRoleSource
Celgene Corp /de/Companynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
GSK PLCFund or asset managernot statednot statedHeld Series A-3 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Hadley Harbor Master Investors (Cayman) L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Sven Ante LundbergPersonnot statednot statedHeld Series B preferred stock (Form 3, 2016)SEC Form 3
Versant Affiliates Fund V, L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Versant Ophthalmic Affiliates I, L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Versant Side Fund IV, L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Versant Venture Capital IV, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Versant Venture Capital V (Canada), LPVenture capitalnot statednot statedHeld Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Versant Venture Capital V, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, A-3 and B preferred stock, 10% owner (Form 3, 2016)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 1 investors.

Largest shareholders today

Institutions holding CRISPR Therapeutics AG shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by CRISPR Therapeutics AG
NameRoleNamed in
James KasingerExecutive officerApr 2020
Lawrence KleinExecutive officerApr 2020
Michael TomsicekExecutive officerApr 2020
Rodger NovakExecutive officerApr 2020
Samarth KulkarniExecutive officerApr 2020
Tony HoExecutive officerApr 2020
Kala Ante SubramanianExecutive officerNov 2016
Marc J. BeckerExecutive officerNov 2016
Samarth Ante KulkarniExecutive officerNov 2016
Sven Ante LundbergExecutive officerNov 2016
Tyler Ante Dylan-HydeExecutive officerNov 2016
Ali BehbahaniDirectorApr 2020
Bradley BolzonDirectorApr 2020
John GreeneDirectorApr 2020
Katherine HighDirectorApr 2020
Rodger NovakDirectorApr 2020
Samarth KulkarniDirectorApr 2020
Simeon GeorgeDirectorApr 2020
Ali Anthony BehbahaniDirectorNov 2016
Bradley Anthony BolzonDirectorNov 2016
Kurt J. von EmsterDirectorNov 2016
N. Anthony ColesDirectorNov 2016
Pablo J. CagnoniDirectorNov 2016
Simeon J. GeorgeDirectorNov 2016
Thomas J. WoiwodeDirectorNov 2016

About

Company in Basel, Switzerland.

Went public since 2016. Its SEC number is that of a company listed on a stock exchange.